From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name
Clinical data
Trade names Renagel, Renvela
AHFS/ monograph
MedlinePlus a601248
Legal status
Routes of
Pharmacokinetic data
Bioavailability nil
Metabolism nil
Biological half-life n/a
Excretion faecal 100%
CAS Registry Number 52757-95-6 YesY
ATC code V03AE02
PubChem CID: 3085017
DrugBank DB00658 N
ChemSpider 2341997 N
KEGG D08512 YesY
Chemical data
Formula [(C3H7N)a+b.(C9H17N2O)c]m
where a+b:c = 9:1
Molecular mass variable
 N (what is this?)  (verify)

Sevelamer (rINN) (/sɛˈvɛləmər/ or /sɛˈvɛləmɪər/) is a phosphate binding drug used to treat hyperphosphatemia in patients with chronic kidney disease. When taken with meals, it binds to dietary phosphate and prevents its absorption. Sevelamer was invented and developed by GelTex Pharmaceuticals. Sevelamer is currently marketed by Sanofi under the trade names Renagel (sevelamer hydrochloride) and Renvela (sevelamer carbonate).

Chemistry and pharmacology[edit]

Sevelamer consists of polyallylamine that is crosslinked with epichlorohydrin.[1] The marketed form sevelamer hydrochloride is a partial hydrochloride salt being present as approximately 40% amine hydrochloride and 60% sevelamer base. The amine groups of sevelamer become partially protonated in the intestine and interact with phosphate ions through ionic and hydrogen bonding.

Clinical use[edit]


Sevelamer is indicated for the management of hyperphosphataemia in adult patients with stage 4 and 5 chronic kidney disease on hemodialysis.


Sevelamer therapy is contraindicated in hypophosphataemia or bowel obstruction.

Adverse effects[edit]

Common adverse drug reactions (ADRs) associated with the use of sevelamer include: hypotension, hypertension, nausea and vomiting, dyspepsia, diarrhea, flatulence, and/or constipation.

Other effects[edit]

Sevelamer can significantly reduce serum uric acid.[2] This reduction has no known detrimental effect and several beneficial effects, including reducing hyperuricemia, uric acid nephrolithiasis, and gout.


  1. ^ (1) Rosenbaum, D. P.; Mandeville, W. H.; Pitruzzello, M.; Goldberg, D. I. Nephrology Dialysis Transplantation Effect of RenaGel A , a Non-Absorbable , Cross-Linked , Polymeric Phosphate Binder , on Urinary Phosphorus Excretion in Rats. 1997, 961–964.
  2. ^ Garg JP, Chasan-Taber S, Blair A et al. (January 2005). "Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial". Arthritis and rheumatism 52 (1): 290–5. doi:10.1002/art.20781. PMID 15641045. 

External links[edit]